-
Sector Analysis
Generalized Pustular Psoriasis (GPP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Generalized Pustular Psoriasis Marketed and Pipeline Drugs Report Overview By 2028, GlobalData estimates that the highest prevalence of GPP cases will be in South Korea and China. Generalized Pustular Psoriasis (GPP) is a subtype of psoriasis in which patients exhibit painful episodes of sterile pustules in their skin. Companies such as AbbVie and academic institutions both are investing heavily in the the clinical trials for GPP. Key Mechanism of Action (Marketed) · Receptor Agonist · Biological Factor Inhibitor · Receptor...
-
Product Insights
Cutaneous Lupus Erythematosus Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Cutaneous Lupus Erythematosus Clinical Trials Overview The Cutaneous Lupus Erythematosus clinical trial report consists of 138 trials. The report provides an overview of the Cutaneous Lupus Erythematosus clinical trials scenario. The report provides top-line data relating to the clinical trials on Cutaneous Lupus Erythematosus. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
-
Product Insights
Hereditary Angioedema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hereditary Angioedema Clinical Trials Market Report Overview There were a total of 204 hereditary angioedema clinical trials conducted as of January 2023. The hereditary angioedema (hae) (c1 esterase inhibitor [c1-inh] deficiency) clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials...
-
Product Insights
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hereditary Angioedema (HAE) Pipeline Drugs Development Market Overview Hereditary Angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids. The Hereditary Angioedema pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hereditary Angioedema, complete with analysis by...
-
Product Insights
Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Sicca Syndrome or Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease. The Sicca Syndrome pipeline drugs market research report provides comprehensive information on the therapeutics under development for Sicca Syndrome, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
Heart Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ...
-
Product Insights
Digital Health Market Size, Share and Trends Analysis by Region, Product, Technology (Telemedicine, mHealth, Digital Therapeutics, Others), Therapy Area (Dermatology, Rheumatology, Gastroenterology) and Segment Forecast, 2022-2027
The digital health in immunology market size was valued at US$6.07 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 24.2% during 2022-2027. Digital health has a broad scope and includes the use of wearable devices, mobile health, telehealth, health information technology, and telemedicine. Digital health applications in immunology have gained significant momentum owing to the following factors: Enhanced access to healthcare Affordable cost of healthcare Improve the quality of care Reduce any...
-
Sector Analysis
EpiCast Report: Systemic Lupus Erythematosus (SLE) – Epidemiology Forecast to 2025
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ system, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. Because of its dynamic nature, this disease has an unpredictable natural course leading to high rates of morbidity and even death. The incidence and prevalence of SLE varies globally and the variation is attributed to a combination of elements...
-
Product Insights
Osteoarthritis Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Osteoarthritis Global Clinical Trials Review, H1, 2016" provides an overview of Osteoarthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Osteoarthritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016" provides an overview of Systemic Sclerosis (Scleroderma) clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Sclerosis (Scleroderma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.